Stock Groups

Is Biofrontera a Good Pharmaceuticals Stock to Own? -Breaking

by Mike Robinson

[ad_1]

© Reuters. Biofrontera is a great stock to own in the pharmaceuticals industry.

Biofrontera, the German biopharmaceutical firm Biofrontera AG’s publicly traded subsidiary that specializes on dermatology products, is Biofrontera (BFRI). Although the company was listed through a traditional IPO in October, its shares are losing momentum. Is BFRI able to use its product mix to accelerate its growth amid this current crisis in public health? Continue reading to learn more.
Biofrontera Inc., a biopharmaceutical firm based in Woburn (Mass.) develops and markets dermatological products for the United States. This is the U.S. affiliate of German biopharmaceutical firm Biofrontera AG.

BFRI’s stock market debut was made recently by a initial public offering (IPO) of 3.60million units at $5 each, which raised $18 million in total proceeds.

Stock traded on the Nasdaq Stock Exchange from October 29. BFRI shares opened at $4.09 the first day of trading, 18.2% lower than its original price target. In the meantime, shares of BFRI have fallen by 1.8%.

Continue reading on StockNews

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]